Biohaven Announces Scientific Leadership Changes

Biohaven Ltd. has announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations.

First, David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, where he will lead the Company’s internal drug-discovery organization, overseeing research programs.

Meanwhile, Dr. Bruce D. Car is retiring as Chief Scientific Officer and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer, effective July 13, 2026. In this role, Car will focus on advancing Biohaven’s scientific initiatives and external collaborations including leading multiple assets under the Company’s collaboration with Bexorg Inc. Car will also continue to serve as an executive officer of the Company.

Lastly, Warren Volles, General Counsel and Chief Legal Officer, has been designated an executive officer of Biohaven and will continue to lead the Company’s legal function.

Vlad Coric, M.D., Chairman and CEO of Biohaven, says these executive transitions “will position us to sustain our discovery momentum and pursue new CNS therapies grounded in human biology and translational innovation.”